Suppr超能文献

健康保险中的另一种事前道德风险。

The other ex ante moral hazard in health.

机构信息

Stanford University School of Medicine, CHP/PCOR, 117 Encina Commons, Stanford, CA 94305-6019, United States.

出版信息

J Health Econ. 2012 Jan;31(1):135-46. doi: 10.1016/j.jhealeco.2011.09.001. Epub 2011 Sep 16.

Abstract

It is well-known that pooled insurance coverage can induce people to make inefficiently low investments in self-protective activities. We identify another ex ante moral hazard that runs in the opposite direction. Lower levels of self-protection and the associated chronic conditions and behavioral patterns such as obesity, smoking, and malnutrition increase the incidence of many diseases and consumption of treatments to those diseases. This increases the reward for innovation and thus benefits the innovator. It also increases treatment innovation which benefits all consumers. As individuals do not take these positive externalities into account, their investments in self-protection are inefficiently high. We quantify the lower bound of this externality for obesity. The lower bound is independent of how much additional innovation is generated. The results show that the externality we identify offsets the negative Medicare-induced insurance externality of obesity. The Medicare-induced obesity subsidy is thus not a sufficient rationale for "soda taxes", "fat taxes" or other penalties on obesity. The quantitative finding also implies that the other ex ante moral hazard that we identify can be as important as the ex ante moral hazard that has been a central concept in health economics for decades.

摘要

众所周知,集合保险覆盖范围可能会诱使人们在自我保护活动上进行低效的低投资。我们发现了另一种事前道德风险,其方向相反。较低水平的自我保护以及相关的慢性疾病和行为模式,如肥胖、吸烟和营养不良,会增加许多疾病的发病率,并增加对这些疾病的治疗消费。这增加了创新的回报,从而使创新者受益。它还增加了治疗创新,使所有消费者受益。由于个人没有考虑到这些正外部性,他们在自我保护方面的投资效率低下。我们对肥胖的这种外部性的下限进行了量化。下限与产生多少额外创新无关。结果表明,我们确定的这种外部性抵消了肥胖对医疗保险的负保险外部性。因此,肥胖引起的医疗保险补贴并不是“苏打税”、“脂肪税”或其他针对肥胖的惩罚的充分理由。这一定量发现还意味着,我们所确定的另一种事前道德风险可能与几十年来一直是健康经济学核心概念的事前道德风险一样重要。

相似文献

1
The other ex ante moral hazard in health.
J Health Econ. 2012 Jan;31(1):135-46. doi: 10.1016/j.jhealeco.2011.09.001. Epub 2011 Sep 16.
2
Moral hazard and selection among the poor: evidence from a randomized experiment.
J Health Econ. 2012 Jan;31(1):72-85. doi: 10.1016/j.jhealeco.2011.12.004. Epub 2012 Jan 3.
3
Optimal commodity taxation with moral hazard and unobservable outcomes.
Int J Health Care Finance Econ. 2003 Mar;3(1):53-71. doi: 10.1023/a:1023272032586.
4
Anticipatory ex ante moral hazard and the effect of Medicare on prevention.
Health Econ. 2011 Sep;20(9):1056-72. doi: 10.1002/hec.1778.
5
Health insurance and ex ante moral hazard: evidence from Medicare.
Int J Health Care Finance Econ. 2009 Dec;9(4):367-90. doi: 10.1007/s10754-009-9056-4. Epub 2009 Mar 11.
6
Ex-ante moral hazard and health insurance: Evidence from China's urban residence basic medical insurance scheme.
Health Econ. 2023 Nov;32(11):2516-2534. doi: 10.1002/hec.4738. Epub 2023 Jul 18.
7
Incentives in obesity and health insurance.
Inquiry. 2009;46(4):418-32. doi: 10.5034/inquiryjrnl_46.4.418.
9
Health insurance and the obesity externality.
Adv Health Econ Health Serv Res. 2007;17:279-318.
10
Is there an ex-ante moral hazard on Indonesia's health insurance? An impact analysis on household waste management behavior.
PLoS One. 2022 Dec 15;17(12):e0276521. doi: 10.1371/journal.pone.0276521. eCollection 2022.

引用本文的文献

1
Older Adults' Preventive Behaviors During COVID-19 Outbreak: Application of Multiple Disadvantage Model.
J Prev (2022). 2022 Aug;43(4):499-511. doi: 10.1007/s10935-022-00689-w. Epub 2022 Jun 17.
3
A comprehensive framework for considering additional unintended consequences in economic evaluation.
Cost Eff Resour Alloc. 2020 Aug 4;18:27. doi: 10.1186/s12962-020-00218-8. eCollection 2020.
4
The effect of Iran's health transformation plan on utilization of specialized outpatient visit services: An interrupted time series.
Med J Islam Repub Iran. 2018 Dec 5;32:121. doi: 10.14196/mjiri.32.121. eCollection 2018.
5
Opportunities and benefits as determinants of the direction of scientific research.
J Health Econ. 2011 Jul;30(4):603-15. doi: 10.1016/j.jhealeco.2011.05.007. Epub 2011 May 25.

本文引用的文献

1
Health Insurance as a Two-Part Pricing Contract.
J Public Econ. 2013 Jun 1;102:1-12. doi: 10.1016/j.jpubeco.2013.03.001.
2
Innovation and The Welfare Effects of Public Drug Insurance.
J Public Econ. 2009 Apr 1;93(3-4):541-548. doi: 10.1016/j.jpubeco.2008.11.003.
3
Incentives in obesity and health insurance.
Inquiry. 2009;46(4):418-32. doi: 10.5034/inquiryjrnl_46.4.418.
4
Health insurance and the obesity externality.
Adv Health Econ Health Serv Res. 2007;17:279-318.
5
The incidence of the healthcare costs of obesity.
J Health Econ. 2009 May;28(3):649-58. doi: 10.1016/j.jhealeco.2009.02.009. Epub 2009 Mar 24.
6
The lifetime medical cost burden of overweight and obesity: implications for obesity prevention.
Obesity (Silver Spring). 2008 Aug;16(8):1843-8. doi: 10.1038/oby.2008.290. Epub 2008 May 29.
7
Market incentives and pharmaceutical innovation.
J Health Econ. 2008 Jul;27(4):1060-1077. doi: 10.1016/j.jhealeco.2008.01.002. Epub 2008 Feb 17.
9
Obesity and the use of health care services.
Obes Res. 2005 Feb;13(2):372-9. doi: 10.1038/oby.2005.49.
10
Economic burden of obesity and its complications in Germany.
Eur J Health Econ. 2003 Nov;4(4):248-53. doi: 10.1007/s10198-003-0178-1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验